369 related articles for article (PubMed ID: 23895801)
1. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.
Everett BM; Pradhan AD; Solomon DH; Paynter N; Macfadyen J; Zaharris E; Gupta M; Clearfield M; Libby P; Hasan AA; Glynn RJ; Ridker PM
Am Heart J; 2013 Aug; 166(2):199-207.e15. PubMed ID: 23895801
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Ridker PM; Everett BM; Pradhan A; MacFadyen JG; Solomon DH; Zaharris E; Mam V; Hasan A; Rosenberg Y; Iturriaga E; Gupta M; Tsigoulis M; Verma S; Clearfield M; Libby P; Goldhaber SZ; Seagle R; Ofori C; Saklayen M; Butman S; Singh N; Le May M; Bertrand O; Johnston J; Paynter NP; Glynn RJ;
N Engl J Med; 2019 Feb; 380(8):752-762. PubMed ID: 30415610
[TBL] [Abstract][Full Text] [Related]
3. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker PM
Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
[TBL] [Abstract][Full Text] [Related]
4. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).
Ridker PM
J Thromb Haemost; 2009 Jul; 7 Suppl 1():332-9. PubMed ID: 19630828
[TBL] [Abstract][Full Text] [Related]
5. Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.
Sparks JA; Barbhaiya M; Karlson EW; Ritter SY; Raychaudhuri S; Corrigan CC; Lu F; Selhub J; Chasman DI; Paynter NP; Ridker PM; Solomon DH
Semin Arthritis Rheum; 2017 Aug; 47(1):133-142. PubMed ID: 28284844
[TBL] [Abstract][Full Text] [Related]
6. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
Ajala ON; Everett BM
Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
8. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
Ridker PM
Curr Atheroscler Rep; 2013 Jan; 15(1):295. PubMed ID: 23225175
[TBL] [Abstract][Full Text] [Related]
9. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
[TBL] [Abstract][Full Text] [Related]
10. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Hartman O; Kovanen PT; Lehtonen J; Eklund KK; Sinisalo J
Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):92-97. PubMed ID: 28025216
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Arca M
Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease.
Reiss AB; Teboul I; Kasselman L; Ahmed S; Carsons SE; De Leon J
J Investig Med; 2022 Aug; 70(6):1433-1437. PubMed ID: 35606100
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
Pradhan AD; Paynter NP; Everett BM; Glynn RJ; Amarenco P; Elam M; Ginsberg H; Hiatt WR; Ishibashi S; Koenig W; Nordestgaard BG; Fruchart JC; Libby P; Ridker PM
Am Heart J; 2018 Dec; 206():80-93. PubMed ID: 30342298
[TBL] [Abstract][Full Text] [Related]
15. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
Gaziano JM; Cincotta AH; Vinik A; Blonde L; Bohannon N; Scranton R
J Am Heart Assoc; 2012 Oct; 1(5):e002279. PubMed ID: 23316290
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
17. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
Ridker PM
Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
[TBL] [Abstract][Full Text] [Related]
19. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.
Muhlestein JB; Lappé DL; Lima JA; Rosen BD; May HT; Knight S; Bluemke DA; Towner SR; Le V; Bair TL; Vavere AL; Anderson JL
JAMA; 2014 Dec; 312(21):2234-43. PubMed ID: 25402757
[TBL] [Abstract][Full Text] [Related]
20. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
